In the phase 3 ADAURA study (NCT02511106) [27], Osimertinib was found to have a clinically meaningful effect on disease-free survival in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC, irrespective of whether patients had previously received chemotherapy or not. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.